 |
|
Tuberculosis drug shows promise against latent bacteria
September 15, 2008Appearing in the Sept. 12 issue of JBC
A new study has shown that an investigational drug (R207910, currently in clinical trials against multi-drug resistant tuberculosis strains) is quite effective at killing latent bacteria. This revelation suggests that R207910 may lead to improved and shortened treatments for this globally prevalent disease.
Despite numerous treatment advances, tuberculosis (TB) remains a serious disease -fueled by co-infection of HIV patients, the rise of drug-resistant strains, and the ability of Mycobacterium tuberculosis to become dormant and linger in the lungs. In fact, one third of the world population is infected, asymptomatically, with latent TB and is at risk of developing active TB disease during their life time.
Anil Koul and colleagues at Johnson & Johnson tested R207910 on dormant M. tuberculosis in three different laboratory models of latency. R207910 targets a protein (ATP synthase) essential for making cellular energy (ATP) in actively replicating TB. The researchers reasoned that even dormant bacteria, which are essentially physiologically "turned off", still need to produce small quantities of ATP to survive. As such, a block in ATP synthesis might be an Achilles heel for killing dormant bacteria.
This reasoning proved to be correct and R207190 was able to kill dormant bacteria by greater than 95% whereas current drugs like isoniazid had no effect. Surprisingly, they found that R207910 is slightly more effective in killing dormant bacteria as compared to actively replicating ones, a unique spin as all known TB drugs are more effective on replicating bugs. Koul and colleagues hope to validate these results clinically, and note that ATP synthase should be looked at as a drug target for other persistent bacterial infections.
American Society for Biochemistry and Molecular Biology
Anil Koul and colleagues at Johnson & Johnson tested R207910 on dormant M. tuberculosis in three different laboratory models of latency. R207910 targets a protein (ATP synthase) essential for making cellular energy (ATP) in actively replicating TB. The researchers reasoned that even dormant bacteria, which are essentially physiologically "turned off", still need to produce small quantities of ATP to survive. As such, a block in ATP synthesis might be an Achilles heel for killing dormant bacteria.
This reasoning proved to be correct and R207190 was able to kill dormant bacteria by greater than 95% whereas current drugs like isoniazid had no effect. Surprisingly, they found that R207910 is slightly more effective in killing dormant bacteria as compared to actively replicating ones, a unique spin as all known TB drugs are more effective on replicating bugs. Koul and colleagues hope to validate these results clinically, and note that ATP synthase should be looked at as a drug target for other persistent bacterial infections.
American Society for Biochemistry and Molecular Biology
Tuberculosis Current Events and Tuberculosis News RSSResearchers identify new leprosy bacterium
A new species of bacterium that causes leprosy has been identified through intensive genetic analysis of a pair of lethal infections, a research team reports in the December issue of the American Journal of Clinical Pathology.
Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
First trachea transplant without immunosuppression
After 4 years of going from consultation to consultation, Claudia Castillo finally found a solution to her respiratory problems. The young Colombian woman suffered from a cough that took a long time to be diagnosed as tuberculosis.
Proteomics Study Yields Clues As To How Tuberculosis Might Be Thwarting The Immune System
A link between the immune system and the self-cleaning system by which biological cells rid themselves of obsolete or toxic parts may one day yield new weapons in the fight against tuberculosis and other deadly infectious diseases.
XDR-TB: Deadlier and more mysterious than ever
New research has found that XDR-TB is increasingly common and more deadly than previously known. Extensively drug-resistant tuberculosis (XDR-TB) is a growing public health threat that is only just beginning to be understood by medical and public health officials.
Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.
Parasites that live inside cells use loophole to thwart immune system
St. Jude Children's Research Hospital scientists have discovered a mechanism by which intracellular pathogens can shut down one of the body's key chemical weapons against them: nitric oxide.
Persistent bacterial infection exploits killing machinery of immune cells
A new study reveals an important and newly discovered pathway used by disease-causing bacteria to evade the host immune system and survive and grow within the very cells meant to destroy them. This discovery may lead to new treatments and vaccines for tuberculosis (TB) and certain other chronic bacterial and parasitic infections.
Health Care Barriers for Undocumented Immigrants: Raising Tuberculosis Risk?
A new study raises the question, do barriers to health care for undocumented immigrants increase the public health risk of tuberculosis? The study, published in the November 15, 2008 issue of Clinical Infectious Diseases and now available online, suggests that undocumented immigrants with tuberculosis have symptoms longer before seeking care than documented immigrants or U.S.-born patients, resulting in more severe symptoms and more opportunities for transmission.
UCLA develops safer, more effective TB vaccine for HIV-positive people
UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials.
More Tuberculosis Current Events and Tuberculosis News Articles
 | The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease by CHARLOTTE ROBERTS, JANE BUIKSTRA Though apparently in decline during the first half of the 20th century, tuberculosis has reawakened in both developed and developing countries, particularly among susceptible populations with immunodeficiency disorders.... |
 | The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost by Frank Ryan Tuberculosis has claimed more than a billion lives worldwide. In this acclaimed book, Dr. Frank Ryan tells the remarkable story of the dedicated doctors, chemists, and bacteriologists who halted the course of this ferocious disease--until the "old enemy" found in AIDS a deadly ally to form a drug-resistant synergy. 8 pages of... |
| Clinician's Guide to Tuberculosis (Clinician's Guide to Tuberculosis (Iseman)) by Michael D. Iseman Written by an eminent tuberculosis specialist from a premier medical institution, this volume is a practical clinical reference on tuberculosis. The major focus is on bedside care, including diagnosis, treatment, and patient management. The author clearly and concisely explains which treatments are most effective and addresses the problems of managing HIV-positive patients and drug-resistant... | |
 | Tuberculosis (TUBERCULOSIS ( ROM)) New York Univ., NY. Summarizes the current advances in tuberculosis and discusses the pathology and pathogenesis of the disease. Also covers complications and treatment options. Chapters include history and epidemiology, genomics and microbiology, host response, therapy, and prevention and control. Previous edition: c1996. DNLM:... |
 | Captain of Death: The Story of Tuberculosis by Thomas M. Daniel The dramatic story of tuberculosis is told here in a straightforward and accessible style. It presents the stories of persons connected with the disease, either as victims, or as those who made contributions to our knowledge of it; in addition to these personal accounts, the book unfolds the history and explains the pathogenesis of TB. The re-emergence of tuberculosis as a major American public... |
 | The White Plague: Tuberculosis, Man, and Society by Rene J. Dubos |
| Diagnostic Standards and Classification of Tuberculosis - by National Tuberculosis and Respiratory Disease Association - | |
| Tuberculosis (Deadly Diseases and Epidemics) by Kim Renee Finer, I. Edward Alcamo Experts in the field of microbiology tell the great "detective stories" of how some of the world's best-known deadly disease-causing microbes were first isolated, identified, and studied. Readers learn how these deadly viruses and bacteria cause disease and what steps have been taken to eradicate them. Tuberculosis killed one out of every seven people living in the United States and Europe in the... | |
 | Tuberculosis and Nontuberculosis Mycobacterial Infections by David Schlossberg The Definitive Text on Tuberculosis Infections for More Than Two Decades!. . This trusted resource provides infectious disease specialists with the most comprehensive coverage found anywhere of the varied manifestations of tuberculin diseases and the clinical options available to physicians for treating them. The new edition has been updated to reflect state-of-the-art changes in the direction... |
 | Tuberculosis (Twenty-First Century Medical Library) by Diane Yancey One of the deadliest diseases healthcare workers fight today, tuberculosis (often called TB) infects the lungs of one-third of the world's population and kills about 2 million people a year. While scientific breakthroughs brought this bacterial disease under control during the 1960s to the 1980s, it was never completely eliminated. In the early 1990s, TB came back as a serious global threat. Not... |
| © 2008 BrightSurf.com |